We are a clinical-stage biopharma company developing new drugs for cardiovascular diseases. Our pipeline focuses on patient populations at high-risk of cardiometabolic complications from underlying chronic inflammation.
Target Oxidized Lipoproteins
Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.
Treat Inflammatory Disease
Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.